Sarepta Therapeutics, Inc.
HealthcareNASDAQ:SRPT · NASDAQ Global Select
+$0.31 today
Vol 2.20M · Avg 3.07M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$713.4M -403.3% | $235.2M +143.9% | -$536.0M +23.8% | -$703.5M -68.0% | -$418.8M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $44.5M +18.0% | $37.7M -15.0% | $44.4M +6.1% | $41.9M +10.1% | $38.0M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 -100.0% | $15.8M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $123.4M -33.0% | $184.3M +1.0% | $182.5M -21.7% | $233.0M +104.5% | $113.9M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $78.0M +110.9% | -$716.6M -49.0% | -$481.1M -1118.9% | -$39.5M +59.8% | -$98.2M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $203.8M +201.0% | -$201.7M -8.6% | -$185.7M -201.3% | -$61.6M -19.3% | -$51.6M | $592.6M | $1.3B | $626.2M |
| Inventory | -$301.1M +23.8% | -$395.2M -167.5% | -$147.7M -190.9% | -$50.8M +39.4% | -$83.8M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $104.3M -5.8% | $110.6M +320.7% | -$50.1M -134.0% | $147.6M +533.4% | $23.3M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $71.1M +130.9% | -$230.4M -136.2% | -$97.5M -30.7% | -$74.6M -634.6% | $14.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $262.0M +389.2% | $53.6M -81.5% | $289.2M +102.6% | $142.7M +251.8% | -$94.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$205.5M +0.1% | -$205.8M +58.9% | -$501.0M -54.0% | -$325.3M +26.6% | -$443.2M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$102.0M +30.6% | -$147.0M -68.2% | -$87.3M -170.8% | -$32.3M +16.2% | -$38.5M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$44.7M +95.9% | -$1.1B +46.3% | -$2.0B -5.7% | -$1.9B -6362.1% | -$30.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $470.0M -76.5% | $2.0B +7.2% | $1.9B +102.4% | $923.2M +98.1% | $466.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$253.7M -2436.9% | -$10.0M -111.0% | $90.8M +6460.3% | -$1.4M -101.5% | $97.9M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $69.6M -90.8% | $755.6M +555.7% | -$165.8M +84.2% | -$1.0B -311.3% | $495.4M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$162.6M -239000.0% | -$68.0K | $0 -100.0% | $304.2M | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $36.3M | $0 | $0 | $0 -100.0% | $548.5M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$25.0M | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$17.1M -113.7% | $124.9M -0.1% | $125.0M +274.4% | -$71.7M -649.7% | $13.0M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$168.3M -234.9% | $124.8M -0.2% | $125.0M -46.2% | $232.5M -58.6% | $561.6M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$304.2M -145.1% | $674.6M +224.5% | -$541.8M +52.5% | -$1.1B -285.7% | $613.8M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$307.5M +12.8% | -$352.7M +40.0% | -$588.3M -64.5% | -$357.6M +25.8% | -$481.7M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.44B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
89bio, Inc.
ETNB
$2.20B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
SEC Filings
Recent regulatory filings
No filings found.
Does SRPT generate free cash flow?
Sarepta Therapeutics, Inc. (SRPT) generated -$307,451,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does SRPT produce?
Operating cash flow was -$205,479,000.00, before capital expenditures of $101.97M.
Explore More
Continue the stock analysis
Jump to another research area for this company.